During preferred speed and simple dual-task walking conditions, patients with Parkinson’s disease, treated with the cholinesterase inhibitor rivastigmine, had a significantly better (reduced) step time variability compared to the placebo-treated group in a simple walking paradigm but there were no significant differences found between the two groups during a complex dual-task walking condition45. The gene discussed is BCHE; the disease is Parkinson disease.